Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaugerre, Constance, Assoumou, Lambert, Maylin, Sarah, Minier, Marine, Gabassi, Audrey, Genin, Michèle, Beniguel, Lydie, Ghosn, Jade, de Lamballerie, Xavier, El Mouhebb, Mayssam, Costagliola, Dominique, Carrat, Fabrice, Molina, Jean Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047207/
https://www.ncbi.nlm.nih.gov/pubmed/35791355
http://dx.doi.org/10.1093/ofid/ofac188
Descripción
Sumario:The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

Ejemplares similares